TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01553305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity exercise programme
Description: Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
Study: NCT03449667

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
Study: NCT01743222

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: eASC
Description: * First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
Study: NCT04252534

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP combined Magnovision
Description: The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Fresh autologous platelet rich plasma, injected subtenon space.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Fresh autologous platelet rich plasma, injected subtenon space.
Study: NCT00288132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
Study: NCT01096875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40mg/day once daily for two weeks prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1tb/day once daily for two weeks prior to surgery
Study: NCT01028820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
Study: NCT02788552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
Study: NCT04210531

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) acute supplementation
Description: One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acute supplementation
Description: One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
Study: NCT01523366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Min - 90mg/Max - 180mg tablets (loading dose)
Study: NCT01553305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Supervised exercise programme
Study: NCT00562705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention
Description: A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention
Study: NCT01523366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg (once daily)/Max - 600mg tablets (loading dose)
Study: NCT04128852

Intervention type: DEVICE
Group type: OTHER
Intervention: MagnetOs Putty
Description: MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
Study: NCT01067053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, capecitabine, oxaliplatin
Description: 6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine
Study: NCT00562705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone-Genotropin or NorditropinSimplex or Biotropin
Description: Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin).
Study: NCT02960854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03879837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate pressurized metered dose inhaler
Description: 110 mcg per actuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent HFA pressurized metered dose inhaler
Description: 110 mcg per actuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pressurized metered dose inhaler
Description: no active content
Study: NCT00093808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT01809223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept, Fixed
Description: intravitreal injection of 0.5 mg conbercept per month, fixed injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conbercept, Fixed
Description: intravitreal injection of 0.5 mg conbercept per month, fixed injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept, PRN
Description: intravitreal injection of 0.5 mg conbercept as need, PRN

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conbercept, PRN
Description: intravitreal injection of 0.5 mg conbercept as need, PRN

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham intravitreal injection per month, fixed injection
Study: NCT03098420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Dexamethasone
Description: 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone
Description: 1 mL (4mg) of dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (TAP blocks)
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (TAP blocks)
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine (TAP blocks)
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 1ml
Description: 1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline 0.5ml
Description: 0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Study: NCT02236104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plethysmography opto electronic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiratory parameters
Study: NCT02222636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline,1 milliliter
Description: Normal saline,1 milliliter, 20 minutes before anaesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg.kg-1,1 milliliter
Description: Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2μg.kg-1,1 milliliter
Description: Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction, 8% sevoflurane
Description: Inhalation induction with 8% sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction, 8% sevoflurane
Description: Inhalation induction with 8% sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction, 8% sevoflurane
Description: Inhalation induction with 8% sevoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
Study: NCT04208776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
Study: NCT03692260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D stent in Herbert screw insertion vs titanium plate
Description: benefit of 3d template in fracture gap
Study: NCT01562509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation tools
Description: * Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: Standard intervention consists of audit\&feedback
Study: NCT03768934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X airtime incentive
Description: An incentive given in the form of airtime.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2X airtime Incentive
Description: An incentive given in the form of airtime.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery airtime incentive
Description: An incentive given in the form of airtime.
Study: NCT01942694

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (Cholecalciferol)
Description: Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as one soft-gel pill daily by mouth
Study: NCT02135796

Intervention type: OTHER
Intervention: Echocardiography
Study: NCT00692302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY
Description: Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
Study: NCT00472576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0657
Description: Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0657
Description: Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily double-blind administration of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily double-blind administration of placebo
Study: NCT03131570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo followed by Secukinumab
Description: Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
Study: NCT00497081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30 mg daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 mg daily for 3 months
Study: NCT03470389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
Study: NCT03859934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment
Study: NCT00692302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY
Description: Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Enhanced usual care will include treatment as usual enhanced by study support.
Study: NCT00994500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT00999804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: 1000 mg of Lapatinib by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg of Lapatinib by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
Study: NCT00994500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00999804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg intravenously, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg intravenously, every 3 weeks
Study: NCT00071058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR9576 (Tariquidar)
Study: NCT02768857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor reeducation programs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor reeducation programs
Study: NCT00816348

Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
Study: NCT00335036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD lead implant
Description: Randomization of ICD lead type at implant
Study: NCT02485535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT02699034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation for typical atrial flutter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision-MR ablation catheter
Study: NCT03726814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPC treatment group
Description: Brain injection EPC
Study: NCT00718640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
Study: NCT02700945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal LINQ™ Insertable Cardiac Monitor
Description: The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
Study: NCT04300101

Intervention type: OTHER
Intervention: molecular characterization
Description: immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis
Study: NCT00335036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thin leads
Description: Thin (less than or equal to 7 French introducer) isodiametric ICD leads
Study: NCT02466893

Intervention type: OTHER
Group type: OTHER
Intervention: Adapt/Standard Stent Retriever (SR) Group
Description: If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.